Dr. Reddy’s names Teva vet COO
Dr. Reddy’s Labs recently made changes to its senior leadership team, spurred by the retirement of COO Abhijit Mukherjee on March 31 after 15 years with the company. Erez Israeli succeeded Mukherjee, effective April 2, becoming the company’s COO and global head of generics and pharmaceutical services and active ingredients.
In his new role, he will report to Dr. Reddy’s co-chairman and CEO G.V. Prasad. Israeli has previously served as president and CEO of Enzymotec, and has more than 25 years’ experience in the pharmaceutical industry. Twenty-three of those years were spent with Teva, where he held various leadership positions, including vice president of North American marketing and sales, vice president of Asia operations, group executive vice president, head of global quality and president and CEO of growth markets, among others.
“I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years,” Prasad said. “I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”
In his new role, he will report to Dr. Reddy’s co-chairman and CEO G.V. Prasad. Israeli has previously served as president and CEO of Enzymotec, and has more than 25 years’ experience in the pharmaceutical industry. Twenty-three of those years were spent with Teva, where he held various leadership positions, including vice president of North American marketing and sales, vice president of Asia operations, group executive vice president, head of global quality and president and CEO of growth markets, among others.
“I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years,” Prasad said. “I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”